Cipla Ltd

Cipla Ltd is up for a fifth straight session today. The stock is quoting at Rs 1517.2, up 0.42% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.38% on the day, quoting at 25199.55. The Sensex is at 82711.36, up 0.39%. Cipla Ltd has gained around 0.37% in last one month. Meanwhile, Nifty Pharma index of which Cipla Ltd is a constituent, has gained around 4.47% in last one month and is currently quoting at 21948, up 0.45% on the day. The volume in the stock stood at 6.69 lakh shares today, compared to the daily average of 19.71 lakh shares in last one month. The benchmark June futures contract for the stock is quoting at Rs 1524.2, up 0.71% on the day. Cipla Ltd is down 1.54% in last one year as compared to a 8.05% jump in NIFTY and a 11.69% jump in the Nifty Pharma index.The PE of the stock is 24.77 based on TTM earnings ending March 25.Powered by Capital Market - Live

Cipla announced that Cipla (EU), UK, a wholly owned subsidiary of the Company, has incorporated a new wholly owned subsidiary named 'CiplaRna GmbH' in Germany, effective 28 May 2025. CiplaRna has been incorporated with the objective of establishing a laboratory for mRNA-based formulation and drug development support.Powered by Capital Market - Live

Jay Precision Pharmaceuticals, subsidiary of Cipla, has completed acquisition of 26% stake in AMPIN Energy C&I Eighteen on 28 May 2025. Powered by Capital Market - Live

Cipla announced that the 89th Annual General Meeting(AGM) of the company will be held on 16 July 2025.Powered by Capital Market - Live

On the segmental front, the company's India business revenue was Rs 2,622 crore (up 8% YoY), North America business revenue was Rs 1,919 crore (up 2% YoY), One Africa business revenue was Rs 1,019 crore (up 20% YoY) and the revenue from Emerging Markets and Europe business was Rs 895 crore (up 21% YoY). Further, the API business revenue and that from Others was Rs 182 crore (down 4% YoY) and Rs 92 crore (down 2 YoY), respectively. While EBITDA rose by 16.8% YoY to Rs 1,538 crore, EBITDA margin expanded by 150 basis points YoY to 22.8% in the fourth quarter. The company's R&D investments stood at Rs 426 crore (or 6.3% of sales) for the quarter, driven by product filings and development efforts. For FY25, Cipla has recorded a consolidated net profit of Rs 5,273 crore (up 28.4% YoY) and total income from operations of Rs 27,548 crore (up 8.2% YoY). The pharmaceutical company had a net cash position of Rs 10,369 crore. The debt primarily included lease liabilities and working capital requirements. Umang Vohra, MD and Global CEO, Cipla, said: 'I am pleased to share that we continue to make considerable progress across our focused markets. In FY25, we recorded a revenue growth of 8% over last year with the EBITDA margin of 25.9%, driven by mix and other operational efficiencies. Our One-India business grew at a healthy 7% YoY. Key therapies in Branded Prescription business continued to outpace the market growth, Trade Generics business growth trajectory is back on track and Anchor brands of Consumer Health Business maintained leadership position. With a positive traction in our differentiated assets, the US business posted an all-time high annual revenue of $ 934 million. In One Africa, we recorded a solid growth of 12% YoY in USD terms, powered by firm performance across key markets. Emerging Markets and Europe delivered a substantial revenue growth of 15% YoY on the back of deep market focus strategy. Going ahead, the focus will be on growing our key markets, further building our flagship brands, investing in future pipeline as well as focusing on resolutions on the regulatory front'. Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolios in our home markets of India, South Africa, North America, and key regulated and emerging markets. The scrip rose 0.40% to currently trade at Rs 1518 on the BSE. Powered by Capital Market - Live

Cipla announced that the Board of Directors of the Company at its meeting held on 13 May 2025, inter alia, have recommended the special dividend of Rs 3 per equity Share (i.e. 150%) , subject to the approval of the shareholders.Powered by Capital Market - Live

Cipla announced that the Board of Directors of the Company at its meeting held on 13 May 2025, inter alia, have recommended the final dividend of Rs 13 per equity Share (i.e. 650%) , subject to the approval of the shareholders.Powered by Capital Market - Live

Net profit of Cipla rose 30.12% to Rs 1221.84 crore in the quarter ended March 2025 as against Rs 939.04 crore during the previous quarter ended March 2024. Sales rose 8.47% to Rs 6597.72 crore in the quarter ended March 2025 as against Rs 6082.37 crore during the previous quarter ended March 2024. For the full year,net profit rose 27.93% to Rs 5272.52 crore in the year ended March 2025 as against Rs 4121.55 crore during the previous year ended March 2024. Sales rose 6.68% to Rs 27145.40 crore in the year ended March 2025 as against Rs 25446.63 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales6597.726082.37 8 27145.4025446.63 7 OPM %23.3021.63 -26.2624.72 - PBDT1813.031547.60 17 7927.766947.74 14 PBT1504.301259.26 19 6820.815896.72 16 NP1221.84939.04 30 5272.524121.55 28 Powered by Capital Market - Live

Cipla has fixed 27 June 2025 as record date for purpose of payment of final dividend, if declared. Powered by Capital Market - Live

According to an exchange filing dated 20 January 2025, the USFDA conducted an inspection of the Medispray facility from 14 to 20 January 2025. The inspection concluded with the issuance of one observation in Form 483. In an email communication dated 11 April 2025, which was received by Cipla on 17 April 2025, the USFDA confirmed the VAI classification for the facility. The official announcement was made on Thursday, 17 April 2025, after market hours. Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolios in our home markets of India, South Africa, North America, and key regulated and emerging markets. The pharma major's consolidated net profit jumped 48.73% to Rs 1,570.51 crore in Q3 FY25 as against Rs 1,055.90 crore reported in Q3 FY24. Total revenue from operations grew by 7.10% year on year (YoY) to Rs 7,072.97 crore in the quarter ended 31 December 2024. The counter rose 0.34% to Rs 1,520.65 on the BSE. Powered by Capital Market - Live